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Abstract: Trimethylamine-N-oxide (TMAO) can be produced by the gut microbiota from dietary
substrates and is associated with cardiovascular disease. While dairy products contain TMAO
precursors, the effect of fermented dairy on TMAO metabolism remains unclear. We used plasma and
urine samples collected for two randomised cross-over studies to evaluate the effects of fermented
dairy consumption on TMAO metabolism. In Study 1, thirteen healthy young men tested a yogurt and
an acidified milk during postprandial tests and a two-week daily intervention. In Study 2, ten healthy
adults tested milk and cheese during postprandial tests. TMAO and five related metabolites were
measured in plasma and urine by LC-MS/MS and NMR. Faecal microbiota composition was assessed
in Study 1 (16S rRNA metagenomics sequencing). Fermented milk products were associated with
lower postprandial TMAO responses than non-fermented milks in urine (Study 1, p = 0.01; Study 2,
p = 0.02) and in plasma, comparing yogurt and acidified milk (Study 1, p = 0.04). Daily consumption
of dairy products did not differentially affect fasting TMAO metabolites. Significant correlations were
observed between microbiota taxa and circulating or urinary TMAO concentrations. Fermentation
of dairy products appear, at least transiently, to affect associations between dairy products and
circulating TMAO levels.
Keywords: TMAO; choline; milk; dairy products; fermented milks; microbiota
1. Introduction
Trimethylamine-N-oxide (TMAO) is an amine oxide that has been associated with the development
of cardiovascular disease (CVD) [1–9]. Several dietary precursors of TMAO, including betaine, choline
and L-carnitine, have also been linked with CVD outcomes [4–6]. The gut microbiota, at the interface
between diet and internal physiology, plays a critical role in mediating the effects of dietary precursors
of TMAO on CVD risk [1–3,5]. The metabolism of these molecules to TMAO is dependent on specific
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microbial metabolism to trimethylamine (TMA) [1,10], an intermediary metabolite which is transported
to the liver where it is oxidised to TMAO [11]. Different substrate-dependent synthesis pathways have
been described for the microbial production of TMA [12], including choline TMA-lyase enzyme (cutC)
that acts with the enzyme activator (cutD) to metabolise choline [13] and carnitine monooxygenase
(cntA/B) that metabolises carnitine [14].
The microbial formation of TMA (and consequently TMAO) is conditioned by the availability
of dietary TMAO precursors. These molecules are present at high levels in animal products [12].
The comparison of high versus low animal product diets has suggested that diet can influence the
formation of TMAO [5,15,16]. Specifically, TMAO was described as one of the most discriminating
metabolites that distinguished the urinary metabolomes of lactovegetarians and omnivorous
subjects [15], while in a cross-over study that imposed a 15 day vegetarian, low meat or high
meat diet, urinary TMAO concentrations were highest after the high meat diet [16]. However,
cross-sectional data for an omnivorous cohort of vascular patients suggested that estimations of TMAO
dietary precursors were neither associated with circulating TMAO nor carotid plaque burden [17].
Furthermore, the explained variance of TMAO in plasma or urine by current diet and covariables
was found to be small in a healthy adult population and appeared to depend upon dietary source of
TMAO [18].
Recently, a novel precursor of TMAO that is metabolised by the gut microbiota has been
identified in ruminant meat and milk, δ-Valerobetaine [19], contributing to the interest to study the
impact of dairy on TMAO metabolism. Other TMAO precursors are found in full fat dairy products,
in particular choline, but tend to present at levels lower than other animal products [20,21]. Remarkably,
a cross-sectional study found that dietary intake of milk and ‘milk and other dairy foods’ were the only
food groups positively associated with plasma TMAO [22]. However, a relative decrease in TMAO was
observed in a cross-over study after a short exposure to diets high in either milk or cheese, with respect
to the control diet that excluded all dairy produce except butter [23].
The interplay between the host gut microbiota, the bacteria present within fermented dairy
products and the variation in TMAO precursors present in dairy products may determine the
associations between dairy products and TMAO. In the current investigation, we test the hypothesis
that the fermentation of dairy products affects plasma and urinary TMAO concentrations after the
consumption of these products. In addition, we sought to explore the potential mechanisms for these
effects on TMAO production by assessing metabolites that are implicated in TMAO metabolism and by
evaluating the impact of the gut microbiota on dairy-induced TMAO production. Our results suggest
that fermented dairy products have different effects to non-fermented dairy products on postprandial
TMAO metabolism. The relationship between dairy products and TMAO appears to be influenced by
the composition of the gut microbiota.
2. Materials and Methods
2.1. Study Design and Subjects
Plasma and urine samples were obtained from two randomised, cross-over trials [24–26] that
assessed the postprandial responses to non-fermented milk and a fermented dairy food. Both studies
were conducted at the Centre of Clinical Research, Lausanne (Switzerland), according to the guidelines
laid down in the Declaration of Helsinki and were approved by the Ethical Committee of the Canton
of Vaud (Switzerland). All study participants gave informed consent for participation. The studies
were registered at clinicaltrials.gov: Study 1, NCT02230345; Study 2, NCT02705560.
Full details of the two study designs, populations and test products are published elsewhere [24,25].
Briefly, Study 1 applied a randomised, double-blind, cross-over design to compare postprandial and
short-term effects of probiotic yogurt to those of an acidified milk in fourteen healthy young men
(Figure 1a) [24]. Subjects were recruited by a poster campaign and screened using strict exclusion
criteria, including abnormal clinical biochemistry, the presence of acute or chronic illness, dietary
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intolerances or allergies, regular medication use and use of antibiotics within the six months prior to
the start of the study (Supplementary Figure S1).
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effects of two-week daily consumption of each product were assessed by fasting tests (Fasting 1 and 
2). (b) In Study 2, test products were administered to volunteers (n = 11) in random order (A = milk, 
B = cheese, C = Soy drink) and their effects were evaluated by postprandial tests. For both studies, on 
postprandial test days, blood (x) and urine sampling (intervals shown by yellow blocks) was 
completed as indicated on the schematics. Fasting blood and urine samples were collected on each 
test day. In Study 1, pre-test faecal samples were collected during the run-in and wash-out phases. 
Dietary restrictions were applied during the studies with the provision of a three-day controlled diet 
(Study 1) and a standardised meal (Study 2) before each test day. 
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C = Soy drink) and their effects were evaluated by postprandial tests. For both studies, on postprandial
test days, blood (x) and urine sampling (intervals shown by yellow blocks) was completed as indicated
on the schematics. Fasting blood and urine samples were collected on each test day. In Study 1, pre-test
faecal samples were collected during the run-in and wash-out phases. Dietary restrictions were applied
during the studies with the provision of a three-day controlled diet (Study 1) and a standardised meal
(Study 2) before each test day.
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The test foods were a fermented yogurt (containing Lactobacillus delbrueckii spp. bulgaricus,
Streptococcus thermophilus and probiotic strain, Lactobacillus rhamnosus GG (ATCC 53103- Culture
Collection of the University of Goteborg, Sweden, reference CCUG 34291) and a milk acidified
with D-(+)-glucono-δ-lactone (2%) to replicate the consistency of yogurt without the addition of a
microorganism (nutrient information of the products was previously reported [24]). Both products
were prepared from the same batch of milk. The products were evaluated after an overnight fast by a
postprandial test comprising a single intake (800 g) of the assigned dairy product (consumed within
15 min), with fasting and 6 h postprandial venous blood and urine sampling. No oral dietary intake
except ad libitum water intake was permitted during the test. This marked the beginning of a two-week
daily consumption of the assigned dairy product (400 g/d), after which, fasting blood and urine samples
were collected. After a three-week wash-out, a second postprandial test and daily consumption period
were completed to assess the other dairy product. Prior to each test day, the volunteers followed a
three-day controlled diet that was adapted to meet the nutritional requirements of each volunteer.
During all study test periods, dietary restrictions limited dairy consumption to products exclusively
provided by the study coordinators. A portion of 400 mL/d full fat milk was provided to volunteers for
the run-in and wash-out phases.
The second study was a randomised, cross-over study that was completed within the framework
of the European JPI-funded project entitled Food Biomarker Alliance (FoodBAll) [27]. As described
previously [25], eleven healthy young men (n = 6) and women (n = 5) were randomly assigned to
test three isocaloric test foods: 600 mL milk, 100 g Gruyère cheese (plus 500 mL still water) and
600 mL soya drink (selected as a non-dairy food) (Figure 1b). Subjects were recruited via a poster
campaign and screened using exclusion criteria, including the presence of chronic or infectious disease,
food intolerances or allergies, anaemia or low ferritin (<30 µg/L) (Supplementary Figure S2). A pre-test
requiring the consumption of 600 mL milk was completed as part of the inclusion protocol to confirm
tolerance to milk. On each test day, participants consumed the assigned test food (within 15 min) after
a 12 h fast and no further food or drink was permitted during the 6 h postprandial phase except for
water (maximum 250 mL/h). Fasting and 6 h postprandial venous blood and urinary sampling were
performed to assess the postprandial responses. A fasting plasma sample was also collected 24 h after
consumption of the foods. Each test day was preceded by two days ‘run-in’, during which strict dietary
restrictions applied that included the total exclusion of dairy and fermented foods, and a standardised
meal (chicken, rice and margarine) on the evening prior to the test day that was followed by a 12 h fast.
Dietary intake was semi-controlled during the 24 h following consumption of the test food.
2.2. Samples
For the purpose of the current analysis, fasting and postprandial, plasma and urine samples
were assessed in a targeted manner for selected metabolites (secondary study outcomes). In Study
1, fasting plasma samples taken on each test day (fasting and dairy test days) and nine postprandial
plasma samples (0.25, 0.5, 1, 1.5, 2, 3, 4, 5 and 6 h) were collected for each dairy test day. In Study
2, baseline fasting plasma sample (collected before each test) and four postprandial plasma samples
(1, 2, 4 and 6 h) collected for the dairy tests (milk and cheese) were assessed in the current analysis.
Samples collected on the non-dairy test day (soja) for the primary objective of the study (to assess food
biomarkers) are not exploited here as we specifically compare fermented and non-fermented dairy
products. All samples were collected and processed according to standard laboratory protocol, before
being stored at −80 ◦C.
Fasting ‘spot’ urine samples were collected for all test days in Study 1 and single pools of urine
were collected in a tube with no additives during the postprandial tests (0–6 h). In Study 2, six pooled
urine samples (0–1, 1–2, 2–4, 4–6, 6–12 and 12–24 h) were collected in the 24 h following consumption
of the test food and were processed as described previously [25]. Urine samples for both studies were
stored at −80 ◦C prior to analysis.
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Faecal samples collected in Study 1 during the run-in period and at the end of the wash-out
period before the postprandial dairy test day were used for microbiota analysis. In a previous analysis,
it was shown that no significant changes in microbiota composition were found between the run-in
and wash-out periods [24]. Nevertheless, the samples collected immediately before the postprandial
test day under consideration were used here (where available) to evaluate the pre-test microbiota
composition. As described previously [24], faecal samples were aliquoted (200 mg) and suspended in
2 mL glycerol-brain heart infusion solution (100 mL glycerol, 37 g brain heart solution, 1 L distilled
water) within 4 h of sample collection and under sterile conditions. All samples were stored after
homogenisation (agitation 13 × g, 10 min) at −80 ◦C prior to DNA extraction.
One volunteer was previously excluded from Study 1 [24] and one individual who did not
participate in the final test day of Study 1 is also not included for any analyses that implied comparisons
with this test day (Supplementary Figure S1). For Study 2, one male volunteer was excluded from
the current analysis due to the detection of abnormal fasting glucose values on multiple test days
(Supplementary Figure S2).
2.3. Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) Analysis of Trimethylamine-N-Oxide
(TMAO) and Related Metabolites
Plasma content of TMAO and five related metabolites (carnitine, betaine, choline,
N,N-dimethylglycine (DMG) and sarcosine) were assessed for both studies by ultra-performance liquid
chromatography–tandem mass spectrometry (UPLC-MS/MS) using an Acquity H-Class coupled with
a Xevo TQD (Waters), as described previously [18,28]. Compounds were separated in HILIC mode
using an inverse acetonitrile gradient on an Acquity BEH Amide column (1.7 µm, 2.1 mm × 100 mm;
Waters) at a flow rate of 0.6 mL/min. Detection was performed by ESI-MRM in positive ion mode with
a solvent delay of one minute. The same approach was adapted to quantify the urinary content of
these metabolites for Study 1. Method modifications include an extension of the analyte panel (not
relevant for the present study), a slightly longer gradient and optimised multiple reaction monitoring
time windows for compound quantification. Further details and basic evaluation data concerning the
modified method are published elsewhere [29,30]. Samples were diluted (urine, ×25; plasma ×10)
with a buffer resembling the LC starting conditions (50% acetonitrile, 50 mM ammonium formate,
adjusted to pH 3.2 with formic acid), and 1 µL was injected. Spiked matrix samples were used for
calibrators and controls (three levels), and isotope-labelled internal standards were used for calibration.
Sample creatinine concentrations were assessed together with the other analytes in the same run and
were used to normalise urine metabolite concentrations (division of metabolite concentrations (µm) by
creatinine (mg/dL)). Since creatinine concentrations are much higher compared to other compounds,
a non-linear calibration and a combination of three internal standards were used.
2.4. NMR Assessment of TMAO
TMAO was assessed in urine collected during Study 2 by NMR, as previously described [25].
Briefly, 1H NMR spectra were measured at 298 K using an AVANCETM III HD 600 MHz spectrometer
(Bruker BioSpin, Karlsruhe, Germany) (proton frequency 600.13 MHz). After pre-processing steps to
acquire spectra, baseline and phase corrections were applied to each spectrum before importing the
spectra into Chenomx (v. 7.72) (Chenomx Inc, Edmonton, Canada) with 1 Hz line-broadening for the
calculation of TMAO concentration. Absolute quantification of TMAO was achieved using TSP (final
concentration of 0.580 mm) as an internal standard. Consequently, no normalisation step was required.
For each sample, the concentration of TMAO was established in 540 µL urine that was measured with
60 µL of phosphate buffer solution containing TSP 0.1%. The quantity of TMAO in the original urine
sample was thus derived by correcting for the addition of the internal standard (division by 0.9) and
multiplying by the total volume of the original sample.
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2.5. 16S rRNA Metagenomic Analysis
As described previously [24], faecal DNA was extracted with QIAamp Fast DNA Stool Mini Kit
(Qiagen, Hilden, Germany). DNA libraries prepared according to the “16S Metagenomic Sequencing
Library Preparation” (Part. # 15044223 Rev. B) protocol from Illumina® (San Diego, CA, USA) were
sequenced on Illumina® MiSeq. Raw reads were processed using the DADA2 R package (1.8.0) [31],
integrated in a Snakemake (5.3.0) [32] pipeline to identify amplicon sequence variants (ASV), which
confer a higher resolution than traditional operational taxonomic unit assignment. Taxonomy was
assigned using the Ribosomal Database Project classifier [33] (QIIME 1.9.1 wrapper [34]) against the
EzBioCloud database (2017-01) [35] and integrated with ASV counts in Phyloseq (1.24.2) [36]. Taxonomic
classification of features displaying significant association (see below, Statistical Analysis) was verified
against the Genome Taxonomy Database (GTDB) [37] (GTDB 16S, revision 89-modified), using the
online Decipher classifier [38] (accessed on 2019/09/23, 50% confidence threshold). ASV counts were
used for functional metagenomic prediction using the PICRUSt2 pipeline (2.1.0_b) [39–43]. PICRUSt2
assigns ASV to reference genomes from which functional and protein annotation were pre-extracted to
depict putative proteins and functions contained within a metagenome. The gene encoding the choline
TMA-lyase enzyme that converts TMA from choline was estimated by targeting the TIGR04394 protein
family (cutC) [44] of the TIGRFAM annotation.
2.6. Statistical Analysis
All statistical analyses were carried out in the R environment (version 3.5.3) [45]. Baseline
inter-day variation in the measured TMAO metabolites was assessed by comparing values of all TMAO
metabolites in fasting samples of plasma and urine between the two dairy test days. The postprandial
changes of circulating metabolites in response to the dairy tests were evaluated by comparison of
the delta change (with respect to fasting levels) for each time point and by comparison of the net
incremental area under the curve (iAUC) for the 6 h postprandial period (linear trapezium method).
The postprandial changes in urinary TMAO metabolites was evaluated for Study 1 by comparing
the metabolite concentrations in the 6 h pooled urine samples between the two dairy tests, while for
Study 2, pairwise comparisons were completed for the cumulative quantities of TMAO at each time
interval assessed during the 24 h following each test. Cumulative quantities of urinary TMAO were
calculated by summation of TMAO found in all the pools within the time interval being assessed,
minus TMAO found in baseline (fasting) samples. For Study 1, the effects of a two-week daily
consumption of dairy on plasma and urine metabolites was evaluated by first assessing for each dairy
product whether a significant change in fasting levels was observed pre versus post the two-week test
period. Subsequently, fasting values after the two-week daily consumption of yogurt versus acidified
milk were compared. For all analyses, the measures for the two dairy tests were compared using a
paired Wilcoxon signed rank test (statistical significance considered at p < 0.05). Carryover effects were
verified where significant differences were observed to confirm the assumption of negligible carryover
effects, according to the procedure described by Wellek and Blettner [46].
Correlation analyses assessed the relationship between TMAO metabolites in blood and urine
using Spearman’s correlation test. Associations for each postprandial and fasting condition, sample
type (i.e., blood or urine) and for each study test day were assessed separately (significance threshold of
false discovery rate (FDR) < 0.05 [47] to account for multiple testing). Where significant differences in
fasting or postprandial responses of metabolites were observed between fermented and non-fermented
dairy products in both urine and plasma, correlation analyses were conducted to confirm that the
trends were associated.
A post hoc microbiota analysis sought to investigate whether the dynamic postprandial response
in TMAO observed in both plasma and urine after the acidified milk test could be explained by features
of the pre-test microbiota composition. Associations between relative abundance of the microbiota
taxa and TMAO (assessed in fasting (baseline) plasma and in urine and plasma collected in the 6 h
postprandial phase after acidified milk consumption) were assessed using the ALDEx2 package [48–50].
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The same analysis strategy was used to evaluate the association between the estimated abundance of
predicted CutC and TMAO concentrations in plasma and urine. ALDEx2 was used to convert counts
to centred log-ratio transformed values (using Monte Carlo sampling), before assessing associations
between these transformed counts and TMAO concentrations in plasma and urine using Spearman’s
rank correlation. Correlations were assessed for taxa (detected in at least five samples) with counts
grouped by hierarchical assignment for all taxonomic levels from ASV to class. Significant associations
were considered if FDR < 0.10 to account for multiple testing [47]. For the targeted assessment of the
protein TIGR04394, significant associations were considered where p < 0.05.
3. Results
3.1. Subject Baseline Characteristics and Samples
The baseline subject characteristics for Studies 1 and 2 confirmed that all subjects were young
(aged 18–39 y), healthy adults (median BMI respectively 22.09 kg/m2 (IQR 20.0–22.69) for Study 1 and
21.8 kg/m2 (IQR 20.8–23.3) for Study 2), as reported previously [24,25]. Targeted metabolite analysis
was completed for samples from thirteen subjects in Study 1 and ten subjects of Study 2. One fasting
urine sample was not available for Study 1 (sample after two-week dairy product consumption)
while two urine samples were missing for Study 2 (6–12 h milk and 12–24 h milk). In both cases,
the corresponding data points for the other dairy test were removed in view of the paired testing
approach. Baseline fasting plasma and urine metabolite concentrations were not significantly different
between the dairy test days for either study (p > 0.05).
3.2. Postprandial Changes in TMAO after Dairy Consumption
The 6 h postprandial TMAO response (net iAUC) in plasma was significantly lower after yogurt
compared to acidified milk consumption in Study 1 (p = 0.04) (Figure 2a). Lower concentrations of
TMAO were found after yogurt consumption for the comparisons at each time point, with significant
differences at 3 h (p = 0.03) (Supplementary Figure S3a). In accordance with the differences observed
for the plasma postprandial responses to acidified milk and yogurt, postprandial urinary TMAO
concentrations in the 6 h postprandial phase were significantly lower after yogurt than acidified milk
(p = 0.01, Figure 2b). These results were partially replicated in Study 2 where a significantly lower
cumulative TMAO urinary excretion was observed after cheese consumption compared to milk for
the interval 0–6 h (p = 0.02, Figure 2d), while plasma TMAO levels were not significantly lower after
cheese compared to milk consumption (net iAUC, p = 0.10) (Figure 2c, Supplementary Figure S4a).
The biological variation of plasma and urine TMAO was consistently lower after fermented dairy
compared to non-fermented milk consumption (Supplementary Table S1). The similar trends in the
postprandial changes in TMAO in plasma and urine were significantly positively associated in the
correlation analyses for Study 1 (Figure 3a) but associations were not significant in Study 2 (Figure 3b).
3.3. Postprandial Changes in TMAO-Related Metabolites and Dairy Consumption
Of the five TMAO-related metabolites that were assessed, no significant differences in the 6 h
postprandial responses were found comparing yogurt and acidified milk (Supplementary Table S2;
Figure S3). Conversely, significantly lower postprandial responses were observed for betaine and choline
after cheese compared to milk consumption in Study 2 (Supplementary Table S3 and Figure S4b,d).
Different effects of the dairy products on metabolite concentrations at specific postprandial time
points were observed for DMG and sarcosine (Supplementary Figures S3 and S4). DMG increased
significantly more at 2 h after yogurt compared to acidified milk consumption (p= 0.002, Supplementary
Figure S3c), while a relative decrease in DMG, which was significantly lower after cheese consumption
compared to that of milk, was observed in Study 2 at 4 h (p = 0.03) and 6 h (p = 0.02) (Supplementary
Figure S4c). No postprandial differences for sarcosine were observed comparing yogurt and acidified
milk (Supplementary Figure S3e), though higher postprandial levels of the metabolite were observed
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at 2 h after cheese consumption compared to that of milk (p = 0.03, Supplementary Figure S4e).
No differences in carnitine postprandial responses to fermented compared to non-fermented milk
consumption were observed for either study (Supplementary Figures S3f and S4f).Nutrients 2020, 12, x FOR PEER REVIEW 8 of 17 
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Figure 3. Scatter plots to illustrate the association between the postprandial TMAO changes in plasma 
(iAUC) and urine (6 h pool) after non-fermented milk (light grey) and fermented dairy (dark grey) 
consumption. Spearman’s correlation test showed positive associations between postprandial TMAO 
(iAUC) in plasma and urine (6 h pool) in Study 1 (a) (acidified milk, rho = 0.48, p = 0.02; yogurt, rho = 
0.39, p = 5 × 10−5) and after milk consumption in Study 2 (b) (milk, rho = 0.52, p = 0.15; cheese, rho = 
0.11, NS). Significant associations at p < 0.05. iAUC, incremental area under the curve; TMAO, 
trimethylamine-N-oxide; Cr, creatinine. 
Figure 2. Postprandial trimethylamine-N-oxide (TMAO) responses in plasma (summarised by net
incremental area under the curve (iAUC)) and urine after consumption of non-fermented milk (light
grey) and a fermented milk product (dark grey) consumption. In Study 1, TMAO responses to acidified
milk (‘A.milk’) and yogurt are compared in (a) plasma and (b) urine. In Study 2, TMAO responses
to milk and cheese are compared in (c) plasma and (d) urine. The concentrations of TMAO after the
dairy products’ tests are compared using the paired Wilcoxon signed-rank test (significance at p < 0.05,
indicated by *). Plots show the IQR (box), the median dividing the IQR (—), wit whiskers that extend
to the last point included in the 1.5 × IQR range and outliers outside this range identified (•).
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(iAUC) and urine (6 h po l) after non-ferme ilk (light grey) and ferm nted dairy (dark grey)
consumption. Spearman’s correlation test sh sitive associations between postpr ndial TMAO
(iAUC) in plasma and urine (6 h pool) in Study 1 (a) (acidified milk, rho = 0.48, p = 0.02; yogurt,
rho = 0.39, p = 5 × 10−5) and after milk consumption in Study 2 (b) (milk, rho = 0.52, p = 0.15; cheese,
rho = 0.11, NS). Significant associations at p < 0.05. iAUC, incremental area under the curve; TMAO,
trimethylamine-N-oxide; Cr, creatinine.
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In Study 1, the 6 h urinary excretion of DMG and betaine were also significantly different
comparing yogurt and acidified milk (Supplementary Table S4). The significantly higher concentrations
of urinary DMG after yogurt as compared with acidified milk corresponded to the differences of
the metabolite in plasma at 2 h. Conversely, while the postprandial changes in plasma betaine were
not different after yogurt compared with acidified milk, the 6 h urinary excretion of betaine was
significantly greater after yogurt consumption. These metabolites were not evaluated in urine for
Study 2.
3.4. Sustained Effects of Dairy Consumption on TMAO and Related Metabolites
A repeated daily exposure to the dairy products did not have a marked effect on TMAO
or TMAO-related metabolites in plasma and urine in Study 1. Fasting plasma levels in TMAO
were not significantly different after two-week daily consumption of acidified milk compared to
yogurt, and neither intervention caused a significant change in fasting plasma with respect to fasting
concentrations taken before the intervention (Supplementary Figure S5). The differences observed
in the postprandial urinary excretion of TMAO after a single 800 g dose of yogurt compared with
acidified milk were not found in the fasting urinary samples that were taken after two-week daily
consumption of the dairy products (p = 0. 23). In Study 2, no significant effects of the dairy products
on TMAO metabolism beyond the 6 h postprandial phase were found in the 12 and 24 h assessments.
3.5. Correlations between TMAO and Related Metabolites
3.5.1. Fasting Analyses
Correlation analyses for fasting plasma metabolites revealed a positive association between
sarcosine and DMG. This was found in three of four fasting assessments in Study 1 (rho = 0.66, 0.56 and
0.43 respectively, for all fasting samples except after two-week acidified milk consumption, FDR < 0.05).
Positive correlations for the same metabolites measured in fasting conditions were also observed in
Study 2 but these associations were not significant. Urinary choline was positively associated with
urinary TMAO in Study 1, but this association was only significant for the assessment before acidified
milk (rho = 0.42, FDR = 0.02).
3.5.2. Postprandial Analyses
Similar postprandial responses were observed for carnitine, betaine and choline in Study 1
(Figure 4). For both acidified milk and yogurt, positive associations were observed in pairwise
comparisons of the three metabolites. These associations were not reproduced in Study 2. Interestingly,
the correlations between the same metabolites in 6 h urine samples only showed a significant association
between choline and betaine, specifically after acidified milk consumption (rho = 0.35, FDR = 0.03).
Other correlations indicated that the circulating postprandial response in TMAO after acidified milk
consumption was inversely associated with that of sarcosine in Study 1 (rho = −0.52, FDR = 0.03) but
not significantly after milk in Study 2 (rho = −0.30, FDR = 0.42). Additionally, the TMAO response to
cheese was positively associated with that of carnitine (rho = 0.59, FDR = 0.02) in Study 2.
3.6. Correlations between Microbiota Taxa and TMAO Concentrations in Blood and Urine
Several inverse associations were identified between fasting TMAO concentrations in plasma
and microbiota taxa (Table 1). These associations included two genera from the Clostridiales order:
Eisenbergiella, from the Lachnospiraceae family and one putative genus (EU844456_g) placed incertae
sedis within the Clostridiales order and the Mogibacterium_f family (a phylotype introduced by the
EzBioCloud database authors [35]). In classification confirmation using GTFB, this feature corresponded
to an undefined genus of the proposed Anaerovoracaceae family. This family was also significantly
inversely associated with fasting TMAO concentrations in plasma.
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Table 1. Spearman’s correlation between fasting plasma TMAO and relative abundance of
microbiota taxa.
Family (EzBioCloud) Family (GTDB) Rho p Value FDR
Mogibacterium_f Anaerovoracaceae −0.61 0.006 0.07 *
Christensenellaceae Unclassified Bacteria −0.58 0.006 0.08 *
Genus (EzBioCloud) Genus (GTDB) Rho p Value FDR
Eisenbergiella Eisenbergiella −0.67 0.001 0.05 *
EU844456_g Unclassified Anaerovoracaceae −0.63 0.003 0.09 *
* Significance for associations with FDR < 0.10. FDR, false discovery rate; TMAO, trimethylamine-N-oxide.
A significant positive association was observed between an uncharacterised genus of the
Lachnospiraceae family, AY305316_g (CAG-81 in GTDB), and the 6 h postprandial urinary TMAO
concentrations after acidified milk consumption (Figure 5). An inverse trend was also observed
between 6 h postprandial urinary TMAO concentrations after acidified milk consumption and the class
Lentisphaeria (rho = −0.65, p = 0.03, FDR = 0.19). Conversely, no significant associations were observed
between postprandial circulating TMAO after acidified milk and microbiota taxa. No associations
were observed between TMAO plasma or urinary concentrations in fasting or postprandial conditions
and the pooled abundance of all taxa predicted to express the cutC gene (p > 0.05).
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4. Discussion
In two human diet intervention studies, we showed lower circulating and urinary TMAO in the
postprandial phase after fermented dairy (yogurt and cheese) consumption compared to non-fermented
dairy consumption. These results were more marked in urine though we found correlations between
plasma and urine TMAO after acidified milk and yogurt interventions. In addition, we identified some
associations between TMAO concentrations (blood and urine) and taxa of the gut microbiota.
Evidence for a modulatory role of dairy products on TMAO concentrations in blood or urine is
inconsistent [18,22,23,51] but this may be explained in part by the type of dairy product considered.
Indeed, Rohrmann et al. [22] already showed that while ‘milk and dairy products’ were positively
associated with plasma TMAO, when ‘milk consumption’ and ‘cheese consumption’ were assessed
separately, the association was only present for milk consumption. Conversely, we previously found no
association between ‘milk and dairy products’ and spot urine TMAO concentrations, but highlighted
a trend for an inverse association between ‘cheese and curd cheese’ consumption and spot urine
TMAO [18]. Certainly, to consider dairy foods as a single, uniform food group does not account for the
highly variable macronutrient content, TMAO substrate availability or presence of bacteria in different
dairy products, all of which can influence TMAO metabolism [1,51–55].
Our observations of lower postprandial TMAO after fermented dairy intake were evident both
when dairy products were matched for caloric load and fat content (Study 1) [24], as well as products
only matched for calorie load but not for macronutrients (Study 2) [25]. It was noteworthy that
different biological variances in postprandial TMAO responses were observed, depending on whether
fermented or non-fermented dairy was consumed. The comparably high inter-individual variation in
the case of the non-fermented milks points to the known influence of various parameters on TMAO
metabolism, including gut microbiota, enzymatic activity and substrate bioavailability. This usual,
well-known variability may be reduced by consumption of bacteria-containing probiotic food such as
yogurt and cheese. This would support a certain levelling of TMAO production as one major aspect of
fermented versus non-fermented dairy.
The postprandial TMAO differences that we observed did not extend to a sustained effect in the
24 h after dairy consumption (Study 2) or following the two-week daily intervention (Study 1). These
results suggest that the observed postprandial increase after non-fermented dairy remains within a
physiological dynamic range that can rapidly stabilise to baseline levels. This is also supported by the
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relatively early peak difference in plasma TMAO at 3 h (Study 1) and by the rapid excretion of the
metabolite that was confirmed in our urinary data. While some circulating TMAO can accumulate in
tissues, it is principally excreted by the kidneys [56,57]. Our findings are in agreement with a cross-over
study that could not confirm a difference in 24 h urinary excretion of TMAO after 14 days of milk-
or cheese-enriched diets, though both dairy products in this case were associated with significant
reductions in TMAO relative to a low-dairy control diet [23].
We found close associations between the three dietary precursors of TMAO, betaine, carnitine and
choline during the postprandial phase, but these metabolites did not show large differences in responses
when comparing our fermented and non-fermented dairy products. This seems to correspond with the
lack of associations between dairy consumption and these metabolites reported by Rohrmann et al. [22].
All of the three precursors are present in dairy products, but for the foods we tested, we estimated that
total choline (14–16 mg/100 g) [20] was much higher than betaine (0.6–0.8 mg/100 g) [20] or L-carnitine
content (1.4–4.2 mg/100 g) [21]. Estimates for the choline content per portion of the dairy products
used in Study 1 were identical (112 mg), corresponding to the lack of difference in the postprandial
dynamics of this metabolite. However, although eucaloric, the cheese and milk portions in Study
2 were not matched for total choline content: estimated 16 mg cheese, 84 mg milk. These choline
differences could be an indirect cause of the higher plasma betaine observed after milk compared to
cheese consumption, though plasma choline actually decreased after both dairy products. At first
glance, the close association between betaine, carnitine and choline in the postprandial phase but not
under fasting conditions is suggestive of a common postprandial dynamic rather than confirmatory of
a true relationship. However, given that the metabolism of choline in the liver and kidney results in its
major metabolite betaine, which can be used to synthesise carnitine [58], the endogenous production
of betaine and carnitine could explain the observed associations.
A role of the gut microbiota on the postprandial increase in TMAO after acidified milk consumption
was suggested by the positive association between an uncharacterised genus of the Lachnospiraceae
family that comprises genera known to express the cutC gene, [9,59] and 6 h postprandial urinary
TMAO concentrations after acidified milk consumption in Study 1. While this association should be
interpreted with some caution given the limited number of subjects included in this analysis, it was
interesting to note that the Lachnospiraceae family have previously been positively associated with
TMAO and TMA in a mice model, with a trend for an association with an increased aortic plaque area [9].
Conversely, a different genus of the Lachnospiraceae family (Eisenbergiella) was inversely associated with
fasting plasma TMAO levels. The finding that two different genera of the same Lachnospiraceae family
exhibit completely different effects on TMAO levels in our study is in line with previous reporting of
wide but uneven distribution of cutC at the genus level and among four different bacterial phyla [60].
This underlines the importance of using adapted amplicon-based metagenomics approaches (in terms
of gene-targeted, amplicon length and reference databases) or shotgun metagenomics in the future to
allow discrimination of bacteria below the genus level. Our targeted assessment of bacteria with the
cutC gene did not confirm an association with these bacteria and TMAO levels after acidified milk
consumption. This may reflect the limitations of the predictive bioinformatic approach that we applied
which, despite the use of ASV, could not capture fine, strain-level presence or absence of the genes of
interest or the variation of gene expression. The lack of associations could also in part be due to the
small sample size in our study, considering that thousands of taxa and their in silico inferred genes
are assessed.
The inverse associations that were identified between the microbiota and baseline fasting TMAO
levels evoke the notion of a competitive influence of the microbiota community or individual bacteria on
TMA-producing bacteria, which has even been suggested as a therapeutic strategy for TMAO-associated
CVD pathologies [9]. Indeed, there has been interest to use probiotic strains to reduce plasma TMAO
elevated, for example, due to a high-fat diet [54] or choline-rich diet [55]. As many fermented dairy
products, including those used in the current study, contain probiotic bacteria, the dietary effects of
fermented dairy products on TMAO metabolism imply a complex interaction of the bacteria present
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in the product itself, the quantity of TMA dietary substrates and the microbiota composition of
the consumer.
A strength in the current work is the use of two independent studies. This allowed us to assess the
robustness of our findings on postprandial TMAO dynamics in different dairy products. It was also
useful to compare the urinary metabolite changes to those observed in plasma to verify the metabolic
fate of the biomarker as well as to confirm that the urinary dynamics corresponded to those of plasma.
The validity of the results was supported by the consistent findings for TMAO in urine for Studies 1
and 2, despite using two different approaches, NMR and mass spectrometry. Furthermore, the use of
cross-over study designs with dietary restrictions during the wash-out phases between each test were
chosen to control for inter-individual variation of TMA-producing strains of the microbiota that may
also account for some of the differences in the reported effects of dairy products on TMAO.
The effects of dairy food consumption on TMAO production seems to depend on the type of
dairy product consumed and the presence of TMA-producing bacteria in the gut microbiota. In the
postprandial phase, we observed differences between fermented and unfermented dairy foods on
urinary and circulating TMAO concentrations. However, further investigations are required to
understand the specificity of these observations to fermentation and to confirm potential health
consequences of such differences.
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